IMAB: I-Mab
About
I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Rockville, MD.
Current Value
$0.981 Year Return
Current Value
$0.981 Year Return
Key Details
Market Cap
$73.40M
P/E Ratio
-0.62
1Y Stock Return
-37.30%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
0.3
Strategies that include IMAB
Stock's related to IMAB
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| WB | 32.77% | $1.41B | -16.20% | 0.00% |
| BZUN | 32.75% | $144.84M | -22.09% | 0.00% |
| MGTX | 32.48% | $467.36M | +9.12% | 0.00% |
| KURA | 31.88% | $1.24B | +70.88% | 0.00% |
| DAO | 31.09% | $159.28M | +25.62% | 0.00% |
| PLL | 30.86% | $238.11M | -56.47% | 0.00% |
| ATUS | 30.61% | $1.10B | -0.42% | 0.00% |
| NNOX | 30.56% | $332.87M | -7.63% | 0.00% |
| QFIN | 28.96% | $5.09B | +95.80% | 3.47% |
| BLNK | 28.89% | $156.82M | -57.53% | 0.00% |
| SPCE | 28.88% | $196.64M | -84.01% | 0.00% |
| HIMS | 28.05% | $5.14B | +210.42% | 0.00% |
| YRD | 28.02% | $518.01M | +101.02% | 3.44% |
| TTEC | 27.72% | $204.76M | -76.19% | 1.39% |
| EH | 27.71% | $689.36M | +1.82% | 0.00% |
| KC | 27.30% | $1.16B | -4.97% | 0.00% |
| SEER | 26.97% | $134.44M | +40.74% | 0.00% |
| KN | 26.60% | $1.60B | +12.19% | 0.00% |
| NMRK | 26.59% | $2.60B | +94.74% | 0.79% |
| PUK | 26.57% | $21.11B | -31.46% | 2.63% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ABR | 0.07% | $2.78B | +21.00% | 11.72% |
| COST | -0.18% | $412.13B | +62.81% | 0.49% |
| KRRO | 0.19% | $436.84M | +20.68% | 0.00% |
| CLPT | 0.22% | $302.60M | +84.68% | 0.00% |
| NTIC | 0.23% | $132.27M | +24.98% | 2.02% |
| DECK | 0.24% | $26.78B | +66.79% | 0.00% |
| PULM | 0.25% | $19.83M | +202.98% | 0.00% |
| DOUG | -0.26% | $208.46M | +40.12% | 0.00% |
| NSSC | -0.27% | $1.33B | +26.57% | 1.12% |
| TXO | -0.28% | $737.26M | -1.80% | 13.22% |
| PINE | -0.28% | $252.63M | +10.21% | 6.30% |
| BERY | 0.30% | $7.61B | +12.08% | 1.61% |
| VMEO | 0.33% | $1.07B | +75.96% | 0.00% |
| MTRX | -0.33% | $358.21M | +30.13% | 0.00% |
| LII | 0.35% | $22.21B | +51.90% | 0.72% |
| SCWX | -0.44% | $743.12M | +40.27% | 0.00% |
| LNN | 0.45% | $1.35B | +3.22% | 1.14% |
| AJG | -0.47% | $64.17B | +17.51% | 0.80% |
| QNRX | 0.52% | $3.20M | -85.07% | 0.00% |
| AXGN | -0.53% | $561.11M | +113.93% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MMYT | -13.82% | $11.31B | +142.64% | 0.00% |
| IBN | -13.52% | $104.98B | +33.69% | 0.80% |
| MUSA | -11.65% | $10.62B | +42.37% | 0.34% |
| LPTH | -10.40% | $62.27M | +33.05% | 0.00% |
| UTI | -9.66% | $1.07B | +73.54% | 0.00% |
| MOH | -9.12% | $16.16B | -21.56% | 0.00% |
| VRCA | -8.89% | $40.58M | -75.88% | 0.00% |
| CHD | -8.63% | $27.18B | +19.50% | 1.03% |
| MELI | -8.59% | $97.16B | +28.15% | 0.00% |
| SUN | -8.41% | $7.32B | +1.51% | 6.47% |
| ACIC | -8.01% | $631.49M | +58.21% | 0.00% |
| OXBR | -7.75% | $19.05M | +178.18% | 0.00% |
| BMA | -7.62% | $5.08B | +232.03% | 6.53% |
| BBAR | -7.00% | $3.52B | +244.80% | 0.00% |
| TEO | -6.89% | $1.69B | +87.97% | 0.00% |
| CEPU | -6.79% | $2.07B | +87.28% | 0.00% |
| IP | -6.79% | $20.09B | +78.02% | 3.20% |
| TGS | -6.74% | $1.97B | +116.04% | 0.00% |
| YPF | -6.59% | $13.98B | +139.72% | 0.00% |
| CSX | -6.49% | $66.72B | +7.29% | 1.36% |
ETF's related to IMAB
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TPMN | -0.22% | $40.60M | 0.65% |
| GSG | -0.50% | $914.42M | 0.75% |
| IBDP | -0.52% | $2.11B | 0.1% |
| SOYB | 1.14% | $27.32M | 0.22% |
| BSCO | -1.19% | $2.35B | 0.1% |
| BILZ | -1.23% | $563.02M | 0.14% |
| SHV | 1.31% | $18.13B | 0.15% |
| IBMM | 1.45% | $391.28M | 0.18% |
| FBY | 1.48% | $127.69M | 0.99% |
| AGZD | -1.70% | $142.76M | 0.23% |
| FLRN | 1.74% | $2.33B | 0.15% |
| DBE | -1.82% | $50.13M | 0.77% |
| COMT | 1.95% | $829.06M | 0.48% |
| DBMF | -2.17% | $1.02B | 0.85% |
| CORN | -2.18% | $61.12M | 0.2% |
| TBLL | 2.27% | $1.92B | 0.08% |
| XBIL | -2.31% | $637.70M | 0.15% |
| PDBC | 2.46% | $4.40B | 0.59% |
| CSHI | 2.70% | $482.85M | 0.38% |
| DBO | -2.85% | $217.57M | 0.77% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -21.36% | $388.04M | 1.43% |
| VIXY | -17.97% | $195.31M | 0.85% |
| USDU | -12.61% | $201.97M | 0.5% |
| UUP | -10.67% | $309.25M | 0.77% |
| BOXX | -10.37% | $4.43B | 0.1949% |
| CTA | -9.65% | $350.27M | 0.78% |
| WEAT | -8.78% | $120.27M | 0.28% |
| IBHD | -8.76% | $327.80M | 0.35% |
| KMLM | -8.70% | $353.87M | 0.9% |
| JBBB | -8.10% | $1.26B | 0.49% |
| TAIL | -7.61% | $67.98M | 0.59% |
| KCCA | -7.51% | $220.51M | 0.87% |
| EQLS | -7.29% | $76.08M | 1% |
| SGOV | -7.07% | $27.53B | 0.09% |
| MINT | -6.31% | $11.62B | 0.35% |
| CLOI | -4.41% | $715.40M | 0.4% |
| TBIL | -3.59% | $4.38B | 0.15% |
| DBO | -2.85% | $217.57M | 0.77% |
| XBIL | -2.31% | $637.70M | 0.15% |
| CORN | -2.18% | $61.12M | 0.2% |
News
Finnhub
The 36th Annual Healthcare Conference will be held in New York, December 3-5, 2024ROCKVILLE, Md., Nov. 21, 2024 /PRNewswire/ -- I-Mab , a U.S.-based global biotech company, exclusively focused on the...
Yahoo
I-Mab ( NASDAQ:IMAB ) Third Quarter 2024 Results Key Financial Results Net loss: US$20.5m (loss narrowed by 57% from 3Q...
Yahoo
I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the three and nine months ended September 30, 2024, and highlighted recent pipeline progress and business updates.
Finnhub
I-Mab Reports Third Quarter 2024 Results • Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data • ...
Finnhub
Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab in...
Yahoo
I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that Sean (Xi-Yong) Fu, PhD, MBA has been appointed as the Company's permanent Chief Executive Officer ("CEO") effective November 1, 2024. Dr. Fu has served as Interim CEO since July 15, 2024. Dr. Fu will continue to serve as a member of the Board of Directors of I-Mab.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.